What is already known about this subject:
- Several clinical trials have indicated that the use of canagliflozin,
a new class of oral antidiabetic drugs that inhibit sodium-glucose
cotransporter 2, increases the risk of lower extremity amputation.
- Diabetes is also a risk of lower extremity amputation.
- FDA had withdrawn its black box warning amputation risk on
canagliflozin, but this risk still exists.